Aytu BioPharma (AYTU) 10-K 1 Sep 16 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Aug. 15, 2016	Dec. 31, 2015
Document Information [Line Items]
Document Type	10-K
Entity Registrant Name	AYTU BIOSCIENCE, INC
Entity Central Index Key	1,385,818
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 9.9
Trading Symbol	AYTU
Entity Common Stock, Shares Outstanding		5,070,591

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Current assets
Cash and cash equivalents	$ 8,054,190	$ 7,353,061
Accounts receivable, net	162,427	157,058
Inventory, net	524,707	39,442
Prepaid expenses and other	215,558	370,888
Prepaid research and development - related party (Note 11)	121,983	121,983
Investment in Acerus	1,041,362	0
Total current assets	10,120,227	8,042,432
Fixed assets, net	231,430	29,706
Developed technology, net	1,159,736	780,125
Customer contracts, net	1,353,375	711,000
Trade names, net	194,472	79,000
Natesto asset	10,549,797	0
Goodwill	221,000	74,000
In-process research and development	0	7,500,000
Patents, net	296,611	628,776
Long-term portion of prepaid research and development - related party (Note 11)	213,471	335,454
Deposits	2,888	4,886
Total non current assets	14,222,780	10,142,947
Total assets	24,343,007	18,185,379
Current liabilities
Accounts payable and accrued liabilities	3,519,711	1,195,368
Natesto payable	5,379,675	0
Accrued compensation	1,200,930	196,503
Deferred revenue	0	85,714
Deferred rent	4,109	0
Total current liabilities	10,104,425	1,477,585
Contingent consideration	3,869,122	664,000
Long-term deferred revenue	0	425,893
Deferred rent	8,215	1,449
Warrant derivative liability	275,992	0
Total liabilities	14,257,754	2,568,927
Commitments and contingencies (Note 7)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued	0	0
Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 3,741,944 in 2016 and 1,188,307 in 2015	374	119
Additional paid-in capital	56,646,304	38,997,674
Ampio stock subscription	0	(5,000,000)
Accumulated deficit	(46,561,425)	(18,381,341)
Total stockholders' equity	10,085,253	15,616,452
Total liabilities and stockholders' equity	$ 24,343,007	$ 18,185,379

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2016	Jun. 30, 2015
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized shares	50,000,000	50,000,000
Preferred stock, issued shares	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized shares	100,000,000	100,000,000
Common stock, issued shares	3,741,944	1,188,307
Common stock, outstanding shares	3,741,944	1,188,307

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Product and service revenue	$ 2,050,838	$ 176,068
License revenue	511,607	85,714
Total revenue	2,562,445	261,782
Operating expenses
Cost of sales	957,076	88,109
Research and development	6,127,772	3,219,361
Research and development - related party (Note 11)	191,991	203,992
Sales, general and administrative	8,517,592	3,980,974
Sales, general and administrative - related party (Note 11)	307,704	311,004
Impairment of intangible assets	7,500,000	0
Amortization of intangible assets	664,707	90,662
Total operating expenses	24,266,842	7,894,102
Loss from operations	(21,704,397)	(7,632,320)
Other (expense)
Interest (expense)	(5,491,486)	(114,994)
Unrealized loss on investment	(971,629)	0
Derivative (expense)	(12,572)	0
Total other (expense)	(6,475,687)	(114,994)
Net loss, before income tax	(28,180,084)	(7,747,314)
Deferred income tax benefit	0	23,910
Net loss	$ (28,180,084)	$ (7,723,404)
Weighted average number of Aytu common shares outstanding (in shares)	1,741,137	767,326
Basic and diluted Aytu net loss per common share (in dollars per share)	$ (16.18)	$ (10.07)

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Ampio Stock Subscription [Member]	Accumulated Deficit [Member]
Balance at Jun. 30, 2014	$ 5,369,407	$ 66	$ 16,027,278	$ 0	$ (10,657,937)
Balance (in shares) at Jun. 30, 2014		658,452
Ampio stock subscription payment	0	$ 18	9,999,982	(10,000,000)	0
Ampio stock subscription payment (in shares)		180,371
Issurance of common stock to Ampio in exchange for Aytu debt	12,000,000	$ 22	11,999,978	0	0
Issurance of common stock to Ampio in exchange for Aytu debt (in shares)		216,445
Ampio stock subscription payment	5,000,000	$ 0	0	5,000,000	0
Issuance of warrants related to the convertible promissory notes	0
Liabilities paid pursuant to the merger	(20,013)	0	(20,013)	0	0
Luoxis options paid-out pursuant to the merger	(27,476)	0	(27,476)	0	0
Reverse merger	0	$ 13	(13)	0	0
Reverse merger (in shares)		133,039
Stock-based compensation	1,017,938	$ 0	1,017,938	0	0
Stock-based compensation (in shares)		0
Net loss	(7,723,404)	$ 0	0	0	(7,723,404)
Balance at Jun. 30, 2015	15,616,452	$ 119	38,997,674	(5,000,000)	(18,381,341)
Balance (in shares) at Jun. 30, 2015		1,188,307
Stock subscription	200,000	$ 3	199,997	0	0
Stock subscription (in shares)		25,641
Ampio stock subscription payment	5,000,000	$ 0	0	5,000,000	0
Conversion of convertible promissory notes and interest to common stock, net of $29,754 conversion costs	10,090,849	$ 96	10,090,753	0	0
Conversion of convertible promissory notes and interest to common stock, net of $29,754 conversion costs (in shares)		962,150
Issuance of warrants related to the convertible promissory notes	136,828	$ 0	136,828	0	0
Issuance of common stock, net of $1,202,231 in issuance costs	4,237,874	$ 156	4,237,718	0	0
Issuance of common stock, net of $1,202,231 in issuance costs (in shares)		1,562,500
Warrants issued in connection with equity financing	2,059,895	$ 0	2,059,895	0	0
Warrants issued in connection with equity financing to the placement agents for the over-allotment option	20,493	0	20,493	0	0
Adjustment for rounding of shares due to stock split	0	$ 0	0	0	0
Adjustment for rounding of shares due to stock split (in shares)		3,346
Stock-based compensation	902,946	$ 0	902,946	0	0
Stock-based compensation (in shares)		0
Net loss	(28,180,084)	$ 0	0	0	(28,180,084)
Balance at Jun. 30, 2016	$ 10,085,253	$ 374	$ 56,646,304	$ 0	$ (46,561,425)
Balance (in shares) at Jun. 30, 2016		3,741,944

Statements of Stockholders' Eq6

Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	Jun. 30, 2016USD ($)
Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs	$ 29,754
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 1,202,231

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Net loss	$ (28,180,084)	$ (7,723,404)
Stock-based compensation expense	902,946	1,017,938
Depreciation, amortization and accretion	874,789	118,202
Asset impairment	7,500,000	0
Amortization of debt issuance costs	182,759	0
Amortization of beneficial conversion feature	4,943,073	0
Noncash interest expense	221,024	0
Derivative expense	12,572	0
Amortization of prepaid research and development - related party (Note 11)	121,983	121,984
Unrecognized loss on investment	971,629	0
Deferred taxes	0	(23,910)
Adjustments to reconcile net loss to net cash used in operating activities:
(Increase) in accounts receivable	(5,369)	(157,058)
(Increase) in inventory	(485,265)	(39,442)
Decrease in prepaid expenses and other	155,330	150,434
(Increase) in prepaid research and development - related party (Note 11)	0	(150,000)
Increase in accounts payable and accrued liabilities	1,623,469	547,314
Increase in accrued compensation	1,004,427	196,503
(Decrease) in payable to Ampio	0	(607,061)
Increase in deferred rent	10,875	0
(Decrease) in deferred revenue	(511,607)	(85,714)
Net cash used in operating activities	(10,657,449)	(6,634,214)
Cash flows used in investing activities
Deposits	1,998	(4,886)
Purchases of fixed assets	(252,932)	0
Purchase of ProstaScint Business	0	(1,000,000)
Purchase of Primsol asset	(1,040,000)
Purchase of Natesto license	(2,000,000)
Investment in Acerus	(2,012,991)
Net cash used in investing activities	(5,303,925)	(1,004,886)
Cash flows from financing activities
Proceeds from convertible note from Ampio converted to stock	0	7,400,000
Proceeds from convertible promissory notes, net (Note 8)	5,175,000	0
Debt issuance costs (Note 8)	(298,322)	0
Costs related to the conversion of the convertible promissory notes to equity	(29,754)	0
Ampio stock subscription payment	5,000,000	5,000,000
Luoxis option payout pursuant to the merger	0	(27,476)
Liabilities paid out pursuant to the merger	0	(20,013)
Sale of stock subscription	200,000	0
Proceeds from issuance of equity financing	7,520,493	0
Issuance costs related to equity financing	(904,914)	0
Net cash provided by financing activities	16,662,503	12,352,511
Net change in cash and cash equivalents	701,129	4,713,411
Cash and cash equivalents at beginning of period	7,353,061	2,639,650
Cash and cash equivalents at end of period	8,054,190	7,353,061
Non-cash transactions:
Ampio stock subscription	0	5,000,000
Ampio unpaid debt converted to stock, received prior to 2015	0	4,600,000
Contingent consideration related to the ProstaScint purchase	0	664,000
Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)	102,931	0
Primsol asset purchase included in primsol payable, $1,250,000 less future accretion of $173,000	1,077,000	0
Conversion of convertible promissory notes and interest of $221,000 to common stock	5,396,024	0
Natesto asset purchase included in Natesto payable, $6,000,000 less future accretion of $620,325	5,379,675	0
Warrant derivative liability related to the issuance of the registered offering placement agent warrants (Note 8)	297,317	0
Reclassification of liability based warrants to equity presentation related to the convertible promissory notes	136,828	0
Beneficial conversion feature related to convertible promissory notes	4,943,073	0
Debt issuance costs related to notes that converted to equity	$ (218,494)	$ 0

Statements of Cash Flows (Paren

Statements of Cash Flows (Parenthetical) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Primsol Business Purchase Included In Primsol Payable Gross	$ 1,250,000	$ 1,250,000
Standardized Measure of Discounted Future Net Cash Flow Relating to Proved Oil and Gas Reserves, Accretion of Discount		$ 173,000	$ 173,000
Conversion of Stock, Shares Issued	221,000	221,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 620,325	$ 620,325
Accretion Expense		$ 6,000,000

Business, Basis of Presentation

Business, Basis of Presentation and Business Combinations	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Business Description and Basis of Presentation [Text Block]	Note 1 – Business, Basis of Presentation and Business Combinations Business Aytu BioScience, Inc. (“Aytu”, the “Company” or “we”) was incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June 8, 2015. Aytu is a commercial-stage specialty healthcare company concentrating on developing and commercializing products with an initial focus on urological diseases and conditions. Aytu is currently focused on addressing significant medical needs in the areas of urological cancers, hypogonadism, urinary tract infections, male infertility, and sexual dysfunction. Basis of Presentation Through a multi-step reverse triangular merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (‘‘Vyrix’’) and Luoxis Diagnostics, Inc. (‘‘Luoxis’’) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding (herein referred to collectively as the “Reverse Stock Splits”). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits. Business Combination—ProstaScint In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (“Jazz Pharmaceuticals”). Pursuant to the agreement, Aytu purchased assets related to the Jazz Pharmaceuticals’ product known as ProstaScint ® 1.0 500,000 227,000 8 2.5 The contingent consideration was initially valued at $ 699,000 2.4 Estimated Tangible assets $ 727,000 Intangible assets 1,590,000 Goodwill 74,000 Total assets acquired $ 2,391,000 Included in the intangible assets is developed technology of $ 790,000 720,000 80,000 159,000 2017 $ 159,000 2018 159,000 2019 159,000 2020 159,000 2021 159,000 Thereafter 616,000 $ 1,411,000 Business Combination—Primsol In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (“FSC”). Pursuant to the agreement, Aytu purchased assets related to FSC’s product known as Primsol® (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the “Primsol Business”), and assumed certain of FSC’s liabilities, including those related to the sale and marketing of Primsol arising after the closing. Aytu paid $ 500,000 142,000 102,000 40,000 500,000 500,000 250,000 Fair Value Tangible assets $ 182,000 Intangible assets 1,470,000 Goodwill 147,000 Total assets acquired $ 1,799,000 Included in tangible assets is $ 102,000 80,000 520,000 810,000 140,000 174,000 As of June 30, 2016, the accrued payable adjusted for the present value was $ 701,000 2017 $ 245,000 2018 245,000 2019 245,000 2020 245,000 2021 245,000 Thereafter 72,000 $ 1,297,000 License and Supply Agreement—Natesto In April, 2016, Aytu entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto® (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we will acquire effective upon the expiration of the current licensee’s rights, which occurred on June 30, 2016. The licensee’s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product. Aytu paid Acerus an upfront fee of $ 2.0 2,000,000 4,000,000 12,245,411 2,534,800 2.0 0.207 0.16 37,500,000 · $ 2,500,000 25,000,000 · $ 5,000,000 50,000,000 · $ 7,500,000 75,000,000 · $ 10,000,000 100,000,000 · $ 12,500,000 125,000,000 The contingent consideration was valued at $ 3.2 10.5 As of June 30, 2016, the accrued payable adjusted for the present value was $ 5.4 3.2

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 – Summary of Significant Accounting Policies Aytu considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments. Aytu’s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year, Aytu has maintained balances in excess of federally insured limits. License Agreements and Royalties Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones and are recognized at the time the milestones are achieved. Royalties will be recognized as revenue when earned. Product & Service Sales Aytu recognizes revenue from product and service sales when there is persuasive evidence that an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured. Aytu records estimated reductions in revenue for potential returns of products by customers. As a result, management must make estimates of potential future product returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different estimates, material differences in the amount of the Company’s reported revenue could result. Accounts receivable are recorded at their net realized value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation allowance accordingly. As of June 30, 2016 we had an allowance for doubtful accounts of $ 41,000 10 10 For the year ended June 30, 2016, one customer accounted for 86 83 At June 30, 2016, 69 99 Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. Aytu periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable value in the period that the impairment is first recognized. Trading securities are carried at fair value with unrealized gains and losses recorded in earnings. Fixed assets are recorded at cost. After being placed in service, the fixed assets are depreciated using the straight-line method over estimated useful lives. Estimated June 30, Useful Lives in years 2016 2015 Office equipment and furniture 3 - 5 $ 201,000 $ - Lab equipment 3 - 5 90,000 90,000 Leasehold improvements 3 45,000 - Manufacturing equipment 5 7,000 - Less accumulated depreciation and amortization (112,000) (60,000) Fixed assets, net $ 231,000 $ 30,000 As of June 30, 2016, Aytu had $ 24,000 Aytu recorded the following depreciation expense in the respective periods: Year Ended June 30, 2016 2015 Depreciation expense $ 51,000 $ 27,000 In-process research and development (“IPRD”) relates to the Company’s Zertane product and clinical trial data acquired in connection with the 2011 acquisition of DMI BioSciences, Inc. (“DMI BioSciences”) by Ampio, the former parent company of Aytu. The $ 7,500,000 Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third party appraisal, was $ 500,000 11 The cost of the Luoxis patents were $ 380,000 15 June 30, 2016 2015 Patents $ 880,000 $ 880,000 Less accumulated amortization (583,000) (251,000) Patents, net $ 297,000 $ 629,000 Year Ended June 30, 2016 2015 Amortization expense $ 332,000 $ 71,000 2017 $ 25,000 2018 25,000 2019 25,000 2020 25,000 2021 25,000 Thereafter 172,000 $ 297,000 The Company accounts for its business acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 805, “Business Combinations”, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. The ProstaScint and Primsol purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below. The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share. The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May 20, 2015 and Primsol that occurred on October 5, 2015. There was no impairment of goodwill for the year ended June 30, 2016. The preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates. Aytu has been included in the consolidated tax returns of Ampio, the former parent company of Aytu, for tax years ended on or before December 31, 2015. As of January 2016, due to the decrease in Ampio’s ownership percentage of Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu’s taxes are computed and reported on a “separate return” basis for these financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The amount of income taxes and related income tax positions taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company’s policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB ASC 740-10, “Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109” (“ASC 740-10”) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant tax position requires recognition under ASC 740-10. Aytu accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the graded method. Research and development costs are expensed as incurred with expenses recorded in the respective period. Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of Aytu. Basic and diluted loss per share was the same in 2016 and 2015. Although there were common stock equivalents of 2,523,929 8,553 Fair Value of Financial Instruments The carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted future cash flows. Aytu accounts for financial instruments (convertible debt with embedded derivative features – conversion options and conversion provisions) and related warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial instruments and related warrants was calculated using a Monte Carlo based valuation model. We recorded a derivative expense at the inception of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods will be recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income or expense for the warrants. The fair value of the warrants issued to the placement agents in connection with the registered offering were valued using the Black-Scholes valuation methodology. Changes in the fair value in subsequent periods were recorded to derivative income or expense. Impairment of Long-Lived Assets Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. Indefinite-lived intangible assets, including acquired IPR&D, are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of the asset to its carrying value, without consideration of any recoverability test. Based on the Company’s evaluation as of June 30, 2016, an impairment existed for IPRD as we do not anticipate any future cash flows from this asset (see In-Process Research and Development). In September 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of March 31, 2016, the Company has early adopted this standard, there was no material impact on our financial statements. In April 2015, the FASB issued ASU 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting” which clarified that the SEC would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. During the quarter ended September 30, 2015, the Company early adopted this standard and recorded debt issuance costs as a debt discount. There was no impact on the Company’s financial statements related to this adoption as the Company did not have any debt issuance costs prior to adoption. In November 2015, the FASB issued ASU No. 2015-17 regarding ASC Topic 470 "Income Taxes: Balance Sheet Classification of Deferred Taxes." The amendments in ASU 2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and require that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial statements. Recently Issued Accounting Pronouncements, Not Adopted as of June 30, 2016 In March 2016, the FASB issued ASU 2016-09, “Compensation –Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting”. The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The amendments are expected to significantly impact net income, earnings per share, and the statement of cash flows. Implementation and administration may present challenges to companies with significant share based payment activities. The amendments are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of this standard on its financial statements however, the Company believes that the impact will not be material. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its financial statements. In January 2016, the FASB issued ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company’s financial position or results of operations. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016, with early adoption permitted. The Company is currently evaluating the impact the adoption of ASU 2014-15 will have on its financial statements. In May 2014, the FASB issuing ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the "New Revenue Standard"). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is not permitted. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019. The Company is evaluating the adoption methodology and the impact of this ASU on its financial statements.

Going Concern

Going Concern	12 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 3 Going Concern As reflected in the accompanying financial statements, the Company has a net loss of $ 28.2 10.7 10.1 46.6 The Company expects that its current cash resources as well as expected lack of operating cash flows will not be sufficient to sustain operations for a period greater than one year. The ability of the Company to continue its operations is dependent on management's plans, which include continuing to raise equity-based financing. There is no assurance that the Company will be successful in accomplishing this objective. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

License Agreement_Revenue Recog

License Agreement/Revenue Recognition	12 Months Ended
	Jun. 30, 2016
Text Block [Abstract]
License Agreement [Text Block]	Note 4 – License Agreement/Revenue Recognition During 2011, Ampio entered into a license, development and commercialization agreement with a major Korean pharmaceutical company which was assigned to Vyrix when it was formed in 2013. The agreement grants the pharmaceutical company exclusive rights to market Zertane in South Korea for the treatment of premature ejaculation (“PE”) and for a combination drug to be developed, utilizing Zertane and an erectile dysfunction drug. Upon signing of the agreement, Ampio received a $ 500,000 418,000 3.2 25 In April 2014, Vyrix entered into a Distribution and License Agreement (the “Paladin Agreement”) with Endo Ventures Limited, which acquired Paladin Labs Inc. (“Paladin”), whereby Paladin has exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub Saharan Africa, Colombia and Latin America. The Paladin Agreement expires on a country by country basis upon the later of 15 250,000 3,025,000 At the end of fiscal 2016, Aytu determined that the Zertane asset has no value as Aytu does not have the resources to complete the necessary clinical trials and bring it to market before the patents expire. The remaining deferred revenue of $ 426,000

Fair Value Considerations

Fair Value Considerations	12 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Consideration [Text Block]	Note 5 – Fair Value Considerations Aytu’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, convertible promissory notes and warrant derivative liability. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the convertible notes was approximately the face value of the notes (see Note 8 for more information). The valuation policies are determined by the Chief Financial Officer and approved by the Company’s Board of Directors. Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu’s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. Aytu’s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Aytu’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented. Fair Value Measurements Using Level 1 Level 2 Level 3 Total June 30, 2016 ASSETS Investment in Acerus $ 1,041,000 $ - $ - $ 1,041,000 LIABILITIES Warrant derivative liability $ - $ - $ 276,000 $ 276,000 Contingent consideration $ - $ - $ 3,869,000 $ 3,869,000 June 30, 2015 ASSETS Investment in Acerus $ - $ - $ - $ - LIABILITIES Warrant derivative liability $ - $ - $ - $ - Contingent consideration $ - $ - $ 664,000 $ 664,000 The estimated fair value of the Company’s investment, which is classified as Level 1 (quoted price is available), was $ 1,041,000 Initial Unrealized As of June 30, 2016 Maturity in Years Cost Gains Losses Fair Value Investment in Acerus Less than 1 year $ 2,013,000 $ 0 $ (972,000) $ 1,041,000 The warrant derivative liability for the warrants was valued using the Black-Scholes valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions in valuing the warrant derivative liability were based on estimates of the value of Aytu common stock, the exercise price of $ 6.00 5 75 1.32 4.84 75 0.986 Derivative Instruments Balance as of June 30, 2015 $ - Warrant issuances 400,000 Reclassification of warrant liability to equity upon note conversion (137,000) Change in fair value included in earnings 13,000 Balance as of June 30, 2016 $ 276,000

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 6 – Income Taxes As previously discussed in Note 2 – Summary of Significant Accounting Policies, the Company has been included in the consolidated tax returns of Ampio for tax years ended on or before December 31, 2015. Beginning in January 2016, Aytu will file tax returns separate from Ampio. For all consolidated tax return periods, the Company's taxes have been computed and reported on a “separate return” basis. Ampio and Aytu do not have a tax sharing agreement. Accordingly, certain tax attributes, e.g., net operating loss carryforwards, reflected in these financial statements, may or may not be available to Aytu. In January 2016, Ampio’s ownership fell below 80% so that Aytu will no longer be included in the Ampio consolidated income tax return. The deconsolidation resulted in approximately $ 4.5 Income tax benefit resulting from applying statutory rates in jurisdictions in which Aytu is taxed (Federal and State of Colorado) differs from the income tax provision (benefit) in the Aytu’s financial statements. Year Ended June 30, 2016 2015 Benefit at statutory rate $ (9,581,229) (34.00) % $ (2,634,087) (34.00) % State income taxes, net of federal benefit (853,203) (3.03) % (216,183) (2.79) % Stock based compensation 7,156 0.03 % 426,725 5.51 % Interest on convertible debt 75,148 0.27 % - 0.00 % Change in valuation allowance 8,672,155 30.77 % 2,397,527 30.95 % Reduction of net operating losses upon deconsolidation 1,674,110 5.94 % - 0.00 % Other 5,863 0.02 % 2,108 0.03 % Net income tax provision (benefit) $ - 0.00 % $ (23,910) (0.30) % Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. 2016 2015 Deferred tax assets (liabilities): Deferred revenue $ - $ 190,000 Deferred rent 5,000 - Accrued expenses 445,000 73,000 Net operating loss carry forward 9,202,000 6,337,000 Intangibles 606,000 453,000 Share-based coompensation 327,000 - Acquired in-process research and development - (2,779,000) Unrealized loss on investment 360,000 - Warrant liability 153,000 - Inventory 192,000 - Allowance for doubtful accounts 15,000 - Total deferred income tax assets (liabilities) 11,305,000 4,274,000 Less: Valuation allowance (11,305,000) (4,274,000) Total deferred income tax assets (liabilities) $ - $ - Aytu has recorded income tax benefits in its statements of operations since inception, stemming from its operating losses, and is expected to incur operating losses for the foreseeable future. During the year ended June 30, 2015, the net deferred tax liability was reduced to zero based upon the operating losses, thus Aytu established a valuation allowance offsetting any future net deferred tax asset. As such, Aytu would no longer record income tax benefits in its results of operations after the year ended June 30, 2015 because management is currently unable to conclude that it is more likely than not that a benefit will be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not it will realize the benefits of these deductible differences, net of the valuation allowance provided. The Company has federal net operating loss carryforwards of approximately $ 24.8 17.1 As of June 30, 2016 and 2015, the Company has no liability for gross unrecognized tax benefits or related interest and penalties. Aytu has made its best estimates of certain income tax amounts included in the financial statements. Application of the Company’s accounting policies and estimates, however, involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, could differ from these estimates. In arriving at its estimates, factors the Company considers include how accurate the estimates or assumptions have been in the past, how much the estimates or assumptions have changed and how reasonably likely such changes may have a material impact. Aytu has been historically included in the Ampio consolidated tax return. Under the general statute of limitations, the Company would not be subject to federal or Colorado income tax examinations for years prior to 2012 and 2011, respectively. However, given the net operating losses generated since inception, all tax years since inception are subject to examination.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 7 – Commitments and Contingencies Total 2017 2018 2019 2020 2021 Thereafter Prescription Database $ 1,902,000 $ 731,000 $ 598,000 $ 573,000 $ - $ - $ - Natesto 8,500,000 6,000,000 - - 2,500,000 - - Manufacturing agreement 3,000,000 2,000,000 500,000 500,000 - - - Service agreement 204,000 204,000 - - - - - Primsol 750,000 750,000 - - - - - Office Lease 317,000 142,000 145,000 30,000 - - - Sponsored research agreement with related party 70,000 70,000 - - - - - $ 14,743,000 $ 9,897,000 $ 1,243,000 $ 1,103,000 $ 2,500,000 $ - $ - Prescription Database In May 2016, Aytu entered into an agreement with a company that will provide Aytu with prescription database information, whereby Aytu agreed to pay approximately $ 1,902,000 Natesto In April 2016, the Company entered into an agreement with Acerus whereby Aytu agreed to pay $ 8,000,000 6,000,000 Manufacturing Agreement On October 8, 2015, Aytu and Biovest International, Inc., or Biovest, entered into a Master Services Agreement, pursuant to which Biovest is to provide manufacturing services to us for ProstaScint. In conjunction with entering into the agreement, we submitted a work order to Biovest to provide us with active pharmaceutical ingredient for ProstaScint over a four-year period at a total cost of $ 5.0 1.0 500,000 2,000,000 500,000 Service Agreement In July 2015, Aytu entered into agreements with Ampio whereby Aytu agreed to pay Ampio $ 30,000 18,000 17,000 310,000 Primsol In October 2015, Aytu entered into an asset purchase agreement with FSC Laboratories, Inc., or FSC. Pursuant to the agreement, we purchased assets related to FSC’s product known as Primsol (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the ‘‘Primsol Business’’), and assumed certain of FSC’s liabilities, including those related to the sale and marketing of Primsol arising after the closing. We paid $ 500,000 142,000 102,000 40,000 500,000 500,000 250,000 1,892,000 Office Lease In June 2015, Aytu entered into a 37 3,000 112,000 37 9,000 318,000 Year Ended June 30, 2016 2015 Rent expense $ 120,000 $ 51,000 Sponsored Research Agreement with Related Party Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (“TRLLC”), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30

Convertible Promissory Notes

Convertible Promissory Notes	12 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 8 – Convertible Promissory Notes Convertible Promissory Notes During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth individual investors for the purchase and sale of convertible promissory notes (“Notes”) with an aggregate principal amount of $ 5.2 401,000 103,000 The Notes were an unsecured obligation. Aytu did not have the right to prepay the Notes prior to the maturity date. Interest accrued on the Notes in the following amounts: (i) 8 12 Placement agents for the offerings sold the institutional portion of the offering of the Notes. Aytu sold the balance of the Notes to individuals and entities with whom Aytu has an established relationship. For Notes sold by the placement agent, Aytu paid the placement agent 8 20,000 The warrants were recorded at fair value as long-term liabilities on the Balance Sheet (see Note 5). Upon Aytu’s adoption of ASU 2015-3, the issuance costs associated with the Notes were recorded as a long–term liability and were presented in the Balance Sheet as a direct reduction of the carrying amount of the Notes on their inception date. Pursuant to the terms of the convertible promissory note agreements, if Aytu sold equity securities at any time while the notes were outstanding in a financing transaction that was not a Qualified Financing (a public offering of Aytu stock resulting in gross proceeds of at least $ 5.0 7.80 4,125,000 143,000 656,591 In May 2016, Aytu completed a registered public offering which was considered a Qualified Financing and all outstanding notes were forced to convert into the same arrangement that was given in the offering. At the insistence of the underwriters of the offering, all outstanding noteholders had signed lockup agreements which granted them an extra 10% on the conversion increasing it to 130% of shares calculated by dividing such note balance by $ 4.80 1,050,000 78,000 305,559 305,559 In connection with the conversion of the Aytu notes, Aytu was obligated to issue to the placement agents for the convertible note offering warrants for an amount of shares equal to 8% of the number of shares of Aytu’s common stock for the notes sold by the placement agents issued upon conversion of the notes. As a result of the optional note conversion, on February 10, 2016, Aytu issued warrants to the placement agents to purchase an aggregate of 22,254 7.80 22,564 4.80 five Also in connection with the conversion of the notes, Aytu recorded a beneficial conversion feature of $ 4.9

Common Stock

Common Stock	12 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Common Stock Capital Stock At June 30, 2016 and 2015, Aytu had 100 300 0.0001 50 0.0001 300 100 In May 2016, we raised gross proceeds of approximately $ 7.5 1,562,500 1.2 6.3 4.2 6.00 2.1 234,375 170,822 0.12 20,000 On June 30, 2016, Aytu effected a reverse stock split in which each common stock holder received one share of common stock for each 12 shares

Equity Instruments

Equity Instruments	12 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 10 – Equity Instruments Options Prior to the Merger, Aytu had two approved stock option plans (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan), pursuant to which Aytu had reserved a total of 143,236 The Luoxis options that were in the money and all outstanding Vyrix options issued under the 2013 Option Plans were accelerated and cancelled in connection with the Merger. Option holders received a cash payment per option share equal to the difference between the consideration payable per share of common stock pursuant to the Merger and the exercise price of the option, if the consideration paid to holders of common stock was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. The cash payment during the period ended June 30, 2015 was $ 27,000 422,000 189,000 433,000 On June 1, 2015, Aytu’s stockholders approved the 2015 Stock Option and Incentive Plan (the “2015 Plan”), which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 833,334 Pursuant to the 2015 Stock Plan, 833,334 Year Ended June 30, 2016 2015 Expected volatility 75 % - Risk free interest rate 1.16% - 1.90 % - Expected term (years) 3.75 - 6.25 - Dividend yield 0 % - Forfeiture rate 0 % - Number of Weighted Weighted Average Outstanding June 30, 2015 - $ - Granted 326,469 $ 18.01 Exercised - $ - Forfeited/Cancelled (4,167) $ 18.12 Outstanding June 30, 2016 322,302 $ 18.01 9.33 Exercisable at June 30, 2016 139,798 $ 16.76 9.42 Available for grant at June 30, 2016 511,032 Range of Exercise Prices Number of Weighted Weighted Number of Weighted $ 6.72 16,668 $ 6.72 9.79 16,668 $ 6.72 $ 18.12 301,467 $ 18.12 9.37 123,130 $ 18.12 $ 55.56 4,167 $ 55.56 4.11 - $ - 322,302 $ 18.01 9.33 139,798 $ 16.76 Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and sales, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. Year Ended June 30, 2016 2015 Research and development expenses Stock options $ 89,000 $ 519,000 Selling, general and administrative expenses Stock options 814,000 499,000 $ 903,000 $ 1,018,000 Unrecognized expense at June 30, 2016 $ 1,267,000 Weighted average remaining years to vest 2.66 Warrants Number of Weighted Weighted Average Outstanding June 30, 2014 8,553 $ 54.36 3.92 Granted in fiscal 2015 - - Expired in fiscal 2015 - - Outstanding June 30, 2015 8,553 $ 54.36 2.92 Warrants issued to placement agents for convertible promissory notes 22,254 $ 7.80 Warrants issued to investors in connection with the registered offering 1,733,322 $ 6.00 Warrants issued to placement agents for convertible promissory notes 22,564 $ 4.80 Warrants issued to placement agents for the registered offering 109,375 $ 6.00 Warrants issued to convertible note holders who converted May 5, 2016 305,559 $ 6.00 Outstanding June 30, 2016 2,201,627 $ 6.19 4.71 5.2 8 In connection with the conversions of the notes in February 2016 and May 2016, which were triggered by an equity financing in January 2016 and our public offering of common stock and warrants in May 2016, respectively, we issued warrants to the placement agents to purchase an aggregate of 22,254 7.80 22,564 4.80 87,000 50,000 Also in connection with the conversion of the notes in May 2016, the noteholders that converted also received 305,559 6.00 480,000 In connection with our May 2016 public offering, we issued warrants to purchase an aggregate of 109,375 6.00 276,000 Also in connection with our May 2016 public offering, we issued to investors warrants to purchase an aggregate of 1,733,322 6.00 The warrants issued in connection with our registered offering are all registered and tradable on the OTCQX under the ticker symbol “AYTUW”. All warrants were valued using the Black-Scholes option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and expected life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. Year Ended June 30, 2016 2015 Expected volatility 75 % - Risk free interest rate 1.07 - 1.76 % - Contractual term (years) 4.2 - 5.0 - Dividend yield 0 % -

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 11 – Related Party Transactions Ampio Loan Agreements In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $ 3,000,000 500,000 1,600,000 3.11 3.32 4,000,000 In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $ 3,000,000 3,000,000 3.11 3.32 8,000,000 On April 16, 2015, Ampio received 396,816 10,000,000 8,000,000 4,000,000 Services Agreement The Company has service agreements with Ampio which are described in Note 7. Sponsored Research Agreement In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio’s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended in January 2015 and provides for Luoxis (now Aytu) to pay $ 6,000 615,000 60.5 March 2019

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Jun. 30, 2016
Postemployment Benefits [Abstract]
Compensation and Employee Benefit Plans [Text Block]	Note 12 – Employee Benefit Plan Aytu has a 401(k) plan that allows participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. As of June 30, 2016, Aytu does not match employee contributions. Starting in fiscal 2017, the Company will match 50% of the first 6% contributed to the plan by employees.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 13 – Subsequent Events In July 2016, Aytu cancelled and re-issued certain outstanding stock option agreements as well as issued an additional 441,999 1.0 133,690 500,000 Under the terms and subject to the conditions of the Purchase Agreement, we have the right to sell to and Lincoln Park is obligated to purchase up to an additional $ 10.0 In connection with the Purchase Agreement, we issued as a commitment fee to Lincoln Park 52,500 50,000 50,000 50,000 50,000

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Aytu considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments. Aytu’s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year, Aytu has maintained balances in excess of federally insured limits.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition License Agreements and Royalties Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones and are recognized at the time the milestones are achieved. Royalties will be recognized as revenue when earned. Product & Service Sales Aytu recognizes revenue from product and service sales when there is persuasive evidence that an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured.
Estimated Sales Returns And Allowances [Policy Text Block]	Estimated Sales Returns and Allowances Aytu records estimated reductions in revenue for potential returns of products by customers. As a result, management must make estimates of potential future product returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different estimates, material differences in the amount of the Company’s reported revenue could result.
Receivables, Policy [Policy Text Block]	Accounts Receivable Accounts receivable are recorded at their net realized value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation allowance accordingly. As of June 30, 2016 we had an allowance for doubtful accounts of $ 41,000 10 10 For the year ended June 30, 2016, one customer accounted for 86 83 At June 30, 2016, 69 99
Inventory, Policy [Policy Text Block]	Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. Aytu periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable value in the period that the impairment is first recognized.
Marketable Securities, Trading Securities, Policy [Policy Text Block]	Trading Securities Trading securities are carried at fair value with unrealized gains and losses recorded in earnings.
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are recorded at cost. After being placed in service, the fixed assets are depreciated using the straight-line method over estimated useful lives. Estimated June 30, Useful Lives in years 2016 2015 Office equipment and furniture 3 - 5 $ 201,000 $ - Lab equipment 3 - 5 90,000 90,000 Leasehold improvements 3 45,000 - Manufacturing equipment 5 7,000 - Less accumulated depreciation and amortization (112,000) (60,000) Fixed assets, net $ 231,000 $ 30,000 As of June 30, 2016, Aytu had $ 24,000 Aytu recorded the following depreciation expense in the respective periods: Year Ended June 30, 2016 2015 Depreciation expense $ 51,000 $ 27,000
In Process Research and Development, Policy [Policy Text Block]	In-Process Research and Development In-process research and development (“IPRD”) relates to the Company’s Zertane product and clinical trial data acquired in connection with the 2011 acquisition of DMI BioSciences, Inc. (“DMI BioSciences”) by Ampio, the former parent company of Aytu. The $ 7,500,000
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third party appraisal, was $ 500,000 11 The cost of the Luoxis patents were $ 380,000 15 June 30, 2016 2015 Patents $ 880,000 $ 880,000 Less accumulated amortization (583,000) (251,000) Patents, net $ 297,000 $ 629,000 Year Ended June 30, 2016 2015 Amortization expense $ 332,000 $ 71,000 2017 $ 25,000 2018 25,000 2019 25,000 2020 25,000 2021 25,000 Thereafter 172,000 $ 297,000
Business Combinations Policy [Policy Text Block]	Business Combinations The Company accounts for its business acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 805, “Business Combinations”, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill The ProstaScint and Primsol purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below. The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share. The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May 20, 2015 and Primsol that occurred on October 5, 2015. There was no impairment of goodwill for the year ended June 30, 2016.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.
Income Tax, Policy [Policy Text Block]	Income Taxes Aytu has been included in the consolidated tax returns of Ampio, the former parent company of Aytu, for tax years ended on or before December 31, 2015. As of January 2016, due to the decrease in Ampio’s ownership percentage of Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu’s taxes are computed and reported on a “separate return” basis for these financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The amount of income taxes and related income tax positions taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company’s policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB ASC 740-10, “Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109” (“ASC 740-10”) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant tax position requires recognition under ASC 740-10.
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation Aytu accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the graded method.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred with expenses recorded in the respective period.
Earnings Per Share, Policy [Policy Text Block]	Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of Aytu. Basic and diluted loss per share was the same in 2016 and 2015. Although there were common stock equivalents of 2,523,929 8,553
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted future cash flows.
Derivatives, Policy [Policy Text Block]	Derivative Liability Aytu accounts for financial instruments (convertible debt with embedded derivative features – conversion options and conversion provisions) and related warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial instruments and related warrants was calculated using a Monte Carlo based valuation model. We recorded a derivative expense at the inception of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods will be recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income or expense for the warrants. The fair value of the warrants issued to the placement agents in connection with the registered offering were valued using the Black-Scholes valuation methodology. Changes in the fair value in subsequent periods were recorded to derivative income or expense.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. Indefinite-lived intangible assets, including acquired IPR&D, are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of the asset to its carrying value, without consideration of any recoverability test. Based on the Company’s evaluation as of June 30, 2016, an impairment existed for IPRD as we do not anticipate any future cash flows from this asset (see In-Process Research and Development).
New Accounting Pronouncements, Policy [Policy Text Block]	Adoption of Newly Issued Accounting Pronouncements In September 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of March 31, 2016, the Company has early adopted this standard, there was no material impact on our financial statements. In April 2015, the FASB issued ASU 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting” which clarified that the SEC would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. During the quarter ended September 30, 2015, the Company early adopted this standard and recorded debt issuance costs as a debt discount. There was no impact on the Company’s financial statements related to this adoption as the Company did not have any debt issuance costs prior to adoption. In November 2015, the FASB issued ASU No. 2015-17 regarding ASC Topic 470 "Income Taxes: Balance Sheet Classification of Deferred Taxes." The amendments in ASU 2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and require that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial statements. Recently Issued Accounting Pronouncements, Not Adopted as of June 30, 2016 In March 2016, the FASB issued ASU 2016-09, “Compensation –Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting”. The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The amendments are expected to significantly impact net income, earnings per share, and the statement of cash flows. Implementation and administration may present challenges to companies with significant share based payment activities. The amendments are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of this standard on its financial statements however, the Company believes that the impact will not be material. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its financial statements. In January 2016, the FASB issued ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company’s financial position or results of operations. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016, with early adoption permitted. The Company is currently evaluating the impact the adoption of ASU 2014-15 will have on its financial statements. In May 2014, the FASB issuing ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the "New Revenue Standard"). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is not permitted. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019. The Company is evaluating the adoption methodology and the impact of this ASU on its financial statements.

Business, Basis of Presentati23

Business, Basis of Presentation and Business Combinations (Tables)	12 Months Ended
	Jun. 30, 2016
Business Description And Basis Of Presentation [Line Items]
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Future amortization from the year ended June 30, 2016 is as follows: 2017 $ 25,000 2018 25,000 2019 25,000 2020 25,000 2021 25,000 Thereafter 172,000 $ 297,000
Primsol Business [Member]
Business Description And Basis Of Presentation [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The Company’s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 is as follows: Fair Value Tangible assets $ 182,000 Intangible assets 1,470,000 Goodwill 147,000 Total assets acquired $ 1,799,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Future amortization from the year ended June 30, 2016 is as follows: 2017 $ 245,000 2018 245,000 2019 245,000 2020 245,000 2021 245,000 Thereafter 72,000 $ 1,297,000
Prostascint Business [Member]
Business Description And Basis Of Presentation [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The Company’s allocation on consideration transferred for ProstaScint as of the purchase date May 20, 2015 is as follows: Estimated Tangible assets $ 727,000 Intangible assets 1,590,000 Goodwill 74,000 Total assets acquired $ 2,391,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Future amortization from the year ended June 30, 2016 is as follows: 2017 $ 159,000 2018 159,000 2019 159,000 2020 159,000 2021 159,000 Thereafter 616,000 $ 1,411,000

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Property, Plant and Equipment [Table Text Block]	Estimated June 30, Useful Lives in years 2016 2015 Office equipment and furniture 3 - 5 $ 201,000 $ - Lab equipment 3 - 5 90,000 90,000 Leasehold improvements 3 45,000 - Manufacturing equipment 5 7,000 - Less accumulated depreciation and amortization (112,000) (60,000) Fixed assets, net $ 231,000 $ 30,000 Aytu recorded the following depreciation expense in the respective periods: Year Ended June 30, 2016 2015 Depreciation expense $ 51,000 $ 27,000
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Patents consist of the following: June 30, 2016 2015 Patents $ 880,000 $ 880,000 Less accumulated amortization (583,000) (251,000) Patents, net $ 297,000 $ 629,000
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Aytu recorded the following amortization expense in the respective periods: Year Ended June 30, 2016 2015 Amortization expense $ 332,000 $ 71,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Future amortization from the year ended June 30, 2016 is as follows: 2017 $ 25,000 2018 25,000 2019 25,000 2020 25,000 2021 25,000 Thereafter 172,000 $ 297,000

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	12 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Financial Assets And Liabilities Not Measured At Fair Value On Recurring Basis [Table Text Block]	The following table presents Aytu’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2016, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total June 30, 2016 ASSETS Investment in Acerus $ 1,041,000 $ - $ - $ 1,041,000 LIABILITIES Warrant derivative liability $ - $ - $ 276,000 $ 276,000 Contingent consideration $ - $ - $ 3,869,000 $ 3,869,000 June 30, 2015 ASSETS Investment in Acerus $ - $ - $ - $ - LIABILITIES Warrant derivative liability $ - $ - $ - $ - Contingent consideration $ - $ - $ 664,000 $ 664,000
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block]	Initial Unrealized As of June 30, 2016 Maturity in Years Cost Gains Losses Fair Value Investment in Acerus Less than 1 year $ 2,013,000 $ 0 $ (972,000) $ 1,041,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy: Derivative Instruments Balance as of June 30, 2015 $ - Warrant issuances 400,000 Reclassification of warrant liability to equity upon note conversion (137,000) Change in fair value included in earnings 13,000 Balance as of June 30, 2016 $ 276,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The following table reflects the reconciliation for the respective periods: Year Ended June 30, 2016 2015 Benefit at statutory rate $ (9,581,229) (34.00) % $ (2,634,087) (34.00) % State income taxes, net of federal benefit (853,203) (3.03) % (216,183) (2.79) % Stock based compensation 7,156 0.03 % 426,725 5.51 % Interest on convertible debt 75,148 0.27 % - 0.00 % Change in valuation allowance 8,672,155 30.77 % 2,397,527 30.95 % Reduction of net operating losses upon deconsolidation 1,674,110 5.94 % - 0.00 % Other 5,863 0.02 % 2,108 0.03 % Net income tax provision (benefit) $ - 0.00 % $ (23,910) (0.30) %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods: 2016 2015 Deferred tax assets (liabilities): Deferred revenue $ - $ 190,000 Deferred rent 5,000 - Accrued expenses 445,000 73,000 Net operating loss carry forward 9,202,000 6,337,000 Intangibles 606,000 453,000 Share-based coompensation 327,000 - Acquired in-process research and development - (2,779,000) Unrealized loss on investment 360,000 - Warrant liability 153,000 - Inventory 192,000 - Allowance for doubtful accounts 15,000 - Total deferred income tax assets (liabilities) 11,305,000 4,274,000 Less: Valuation allowance (11,305,000) (4,274,000) Total deferred income tax assets (liabilities) $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies Disclosure [Table Text Block]	Commitments and contingencies are described below and summarized by the following table as of June 30, 2016: Total 2017 2018 2019 2020 2021 Thereafter Prescription Database $ 1,902,000 $ 731,000 $ 598,000 $ 573,000 $ - $ - $ - Natesto 8,500,000 6,000,000 - - 2,500,000 - - Manufacturing agreement 3,000,000 2,000,000 500,000 500,000 - - - Service agreement 204,000 204,000 - - - - - Primsol 750,000 750,000 - - - - - Office Lease 317,000 142,000 145,000 30,000 - - - Sponsored research agreement with related party 70,000 70,000 - - - - - $ 14,743,000 $ 9,897,000 $ 1,243,000 $ 1,103,000 $ 2,500,000 $ - $ -
Schedule of Rent Expense [Table Text Block]	Rent expense for the respective periods is as follows: Year Ended June 30, 2016 2015 Rent expense $ 120,000 $ 51,000

Equity Instruments (Tables)

Equity Instruments (Tables)	12 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The assumptions are as follows: Year Ended June 30, 2016 2015 Expected volatility 75 % - Risk free interest rate 1.16% - 1.90 % - Expected term (years) 3.75 - 6.25 - Dividend yield 0 % - Forfeiture rate 0 % -
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock option activity is as follows: Number of Weighted Weighted Average Outstanding June 30, 2015 - $ - Granted 326,469 $ 18.01 Exercised - $ - Forfeited/Cancelled (4,167) $ 18.12 Outstanding June 30, 2016 322,302 $ 18.01 9.33 Exercisable at June 30, 2016 139,798 $ 16.76 9.42 Available for grant at June 30, 2016 511,032
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table details the options outstanding at June 30, 2016 by range of exercise prices: Range of Exercise Prices Number of Weighted Weighted Number of Weighted $ 6.72 16,668 $ 6.72 9.79 16,668 $ 6.72 $ 18.12 301,467 $ 18.12 9.37 123,130 $ 18.12 $ 55.56 4,167 $ 55.56 4.11 - $ - 322,302 $ 18.01 9.33 139,798 $ 16.76
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The following table summarizes stock-based compensation expense for the years ended June 30 2016 and 2015: Year Ended June 30, 2016 2015 Research and development expenses Stock options $ 89,000 $ 519,000 Selling, general and administrative expenses Stock options 814,000 499,000 $ 903,000 $ 1,018,000 Unrecognized expense at June 30, 2016 $ 1,267,000 Weighted average remaining years to vest 2.66
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of all warrants is as follows: Number of Weighted Weighted Average Outstanding June 30, 2014 8,553 $ 54.36 3.92 Granted in fiscal 2015 - - Expired in fiscal 2015 - - Outstanding June 30, 2015 8,553 $ 54.36 2.92 Warrants issued to placement agents for convertible promissory notes 22,254 $ 7.80 Warrants issued to investors in connection with the registered offering 1,733,322 $ 6.00 Warrants issued to placement agents for convertible promissory notes 22,564 $ 4.80 Warrants issued to placement agents for the registered offering 109,375 $ 6.00 Warrants issued to convertible note holders who converted May 5, 2016 305,559 $ 6.00 Outstanding June 30, 2016 2,201,627 $ 6.19 4.71
Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]	The assumptions are as follows: Year Ended June 30, 2016 2015 Expected volatility 75 % - Risk free interest rate 1.07 - 1.76 % - Contractual term (years) 4.2 - 5.0 - Dividend yield 0 % -

Business, Basis of Presentati29

Business, Basis of Presentation and Business Combinations (Details) - USD ($)	Jun. 30, 2016	Oct. 05, 2015	Jun. 30, 2015	May 31, 2015	May 20, 2015
Business Acquisition [Line Items]
Goodwill	$ 221,000		$ 74,000
Prostascint Business [Member]
Business Acquisition [Line Items]
Tangible assets					$ 727,000
Intangible assets					1,590,000
Goodwill					74,000
Total assets acquired				$ 2,400,000	$ 2,391,000
Primsol Business [Member]
Business Acquisition [Line Items]
Tangible assets		$ 182,000
Intangible assets		1,470,000
Goodwill		147,000
Total assets acquired		$ 1,799,000

Business, Basis of Presentati30

Business, Basis of Presentation and Business Combinations (Details 1) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Patents, net	$ 296,611	$ 628,776
Prostascint Business [Member]
Finite-Lived Intangible Assets [Line Items]
2,017	159,000
2,018	159,000
2,019	159,000
2,020	159,000
2,021	159,000
Thereafter	616,000
Patents, net	1,411,000
Primsol Business [Member]
Finite-Lived Intangible Assets [Line Items]
2,017	245,000
2,018	245,000
2,019	245,000
2,020	245,000
2,021	245,000
Thereafter	72,000
Patents, net	$ 1,297,000

Business, Basis of Presentati31

Business, Basis of Presentation and Business Combinations (Details Textual)	1 Months Ended					12 Months Ended
	Apr. 28, 2016USD ($)$ / sharesshares	Oct. 31, 2015USD ($)	Oct. 05, 2015USD ($)	Sep. 30, 2015USD ($)	May 31, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Apr. 28, 2016CADCAD / shares	May 20, 2015USD ($)
Business Acquisition [Line Items]
Stockholders' Equity, Reverse Stock Split						On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding (herein referred to collectively as the “Reverse Stock Splits”).
Payments to Acquire Businesses, Gross						$ 0	$ 1,000,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset						0	664,000
Amortization of Intangible Assets			$ 174,000			664,707	$ 90,662
Business Combination, Contingent Consideration, Liability, Total						701,000
Developed Technology Rights [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets						520,000
Trade Names [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets						140,000
Customer Contracts [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets						810,000
Prostascint Business [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total					$ 2,400,000				$ 2,391,000
Payments to Acquire Businesses, Gross					1,000,000
Business Combination, Consideration Transferred, Liabilities Incurred				$ 227,000
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High					$ 2,500,000
Business Combination Contingent Consideration Percentage					8.00%
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset					$ 664,000	699,000
Business Combination Consideration Transferred Product Inventory					$ 500,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross						790,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross						80,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Customer Contracts [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross						720,000
Primsol Business [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total			$ 1,799,000
Payments to Acquire Businesses, Gross		$ 500,000
Business Combination, Consideration Transferred, Liabilities Incurred		142,000				1,892,000
Business Combination Consideration Transferred Inventory		102,000				102,000
Business Combination Consideration Transferred Product Inventory		40,000
Business Combination Consideration Transferred Work In Process Inventory						80,000
Primsol Business [Member] | Paid on April 1, 2016 [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred		500,000
Primsol Business [Member] | No Later Than July 01, 2016 [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred		500,000
Primsol Business [Member] | No Later Than September 30, 2016 [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred		$ 250,000
Natesto [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total						10,500,000
Payments to Acquire Businesses, Gross	$ 2,000,000					5,400,000
Business Combination, Consideration Transferred, Liabilities Incurred						3,200,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset						$ 3,200,000
Finite-Lived Intangible Assets, Remaining Amortization Period						8 years
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares	12,245,411
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2,000,000							CAD 2,534,800
Business Acquisition, Share Price | (per share)	$ 0.16							CAD 0.207
One Time Non-Refundable Payments	$ 37,500,000
Natesto [Member] | First Milestone [Member] | License And Supply Agreement [Member]
Business Acquisition [Line Items]
One Time Non-Refundable Payments	2,500,000
Sales Revenue Target	25,000,000
Natesto [Member] | Second Milestone [Member] | License And Supply Agreement [Member]
Business Acquisition [Line Items]
One Time Non-Refundable Payments	5,000,000
Sales Revenue Target	50,000,000
Natesto [Member] | Third Milestone [Member] | License And Supply Agreement [Member]
Business Acquisition [Line Items]
One Time Non-Refundable Payments	7,500,000
Sales Revenue Target	75,000,000
Natesto [Member] | Forth Milestone [Member] | License And Supply Agreement [Member]
Business Acquisition [Line Items]
One Time Non-Refundable Payments	10,000,000
Sales Revenue Target	100,000,000
Natesto [Member] | Fifth Milestone [Member] | License And Supply Agreement [Member]
Business Acquisition [Line Items]
One Time Non-Refundable Payments	12,500,000
Sales Revenue Target	125,000,000
Natesto [Member] | Second Upfront [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred	2,000,000
Natesto [Member] | Third Upfront [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred	$ 4,000,000

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Less accumulated depreciation and amortization	$ (112,000)	$ (60,000)
Fixed assets, net	231,430	29,706
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 201,000	0
Office equipment and furniture [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Office equipment and furniture [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 90,000	90,000
Lab equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Lab equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 45,000	0
Estimated useful lives	3 years
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 7,000	$ 0
Estimated useful lives	5 years

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 51,000	$ 27,000

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Details 2) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Indefinite-lived Intangible Assets [Line Items]
Patents, net	$ 296,611	$ 628,776
Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
Patents	880,000	880,000
Less accumulated armortization	(583,000)	(251,000)
Patents, net	$ 297,000	$ 629,000

Summary of Significant Accoun35

Summary of Significant Accounting Policies (Details 3) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 05, 2015	Jun. 30, 2016	Jun. 30, 2015
Amortization expense	$ 174,000	$ 664,707	$ 90,662

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Details 4) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Indefinite-lived Intangible Assets [Line Items]
Patents, net	$ 296,611	$ 628,776
Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
2,017	25,000
2,018	25,000
2,019	25,000
2,020	25,000
2,021	25,000
Thereafter	172,000
Patents, net	$ 297,000	$ 629,000

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Summary Of Significant Accounting Policy [Line Items]
Allowance for Doubtful Accounts Receivable	$ 41,000	$ 0
Indefinite Lived Intangible Asset In Process Research And Development	0	$ 7,500,000
Goodwill, Impairment Loss	$ 0
Stock Options [Member]
Summary Of Significant Accounting Policy [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,523,929
Warrant [Member]
Summary Of Significant Accounting Policy [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		8,553
Customer One [Member] | Sales Revenue Gross [Member]
Summary Of Significant Accounting Policy [Line Items]
Concentration Risk, Percentage	86.00%	83.00%
Customer One [Member] | Accounts Receivable Net [Member]
Summary Of Significant Accounting Policy [Line Items]
Concentration Risk, Percentage	10.00%
Customer One [Member] | Sales Revenue, Net [Member]
Summary Of Significant Accounting Policy [Line Items]
Concentration Risk, Percentage	10.00%
Customer One [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policy [Line Items]
Concentration Risk, Percentage	69.00%	99.00%
Office Equipment [Member]
Summary Of Significant Accounting Policy [Line Items]
Phone System And Enterprise Resource System	$ 24,000
Zertane Patents [Member]
Summary Of Significant Accounting Policy [Line Items]
Finite-Lived Intangible Assets, Gross	$ 500,000
Finite-Lived Intangible Assets, Remaining Amortization Period	11 years
Finite Lived Intangible Assets Expiration Month Year	2022-03
Orp [Member]
Summary Of Significant Accounting Policy [Line Items]
Finite-Lived Intangible Assets, Gross	$ 380,000
Finite-Lived Intangible Assets, Remaining Amortization Period	15 years
Finite Lived Intangible Assets Expiration Month Year	2028-03

Going Concern (Details Textual)

Going Concern (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Net Income (Loss) Attributable to Parent, Total	$ (28,180,084)	$ (7,723,404)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	(10,657,449)	(6,634,214)
Stockholders' Equity Attributable to Parent, Total	10,085,253	15,616,452	$ 5,369,407
Retained Earnings (Accumulated Deficit), Total	$ (46,561,425)	$ (18,381,341)

License Agreement_Revenue Rec39

License Agreement/Revenue Recognition (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2014	Jun. 30, 2016
Revenue Recognition [Line Items]
Deferred Revenue		$ 426,000
Vyrix Pharmaceuticals Inc [Member]
Revenue Recognition [Line Items]
Potential Milestone Payments Receivable	$ 3,025,000
Deferred Revenue	$ 250,000
Deferred Revenue Recognition Period	7 years
Agreement Expiration Period	15 years
Ampio [Member]
Revenue Recognition [Line Items]
Potential Milestone Payments Receivable		$ 3,200,000
Percentage Of Royalty Rate Of Net Sales		25.00%
Deferred Revenue		$ 500,000
Proceeds from License Fees Received		$ 418,000
Deferred Revenue Recognition Period		10 years

Fair Value Considerations (Deta

Fair Value Considerations (Details) - USD ($)	Jun. 30, 2016	Aug. 31, 2015	Jun. 30, 2015
ASSETS
Investment in Acerus	$ 1,041,000		$ 0
LIABILITIES
Warrant derivative liability	275,992	$ 103,000	0
Contingent consideration	3,869,122		664,000
Fair Value, Inputs, Level 1 [Member]
ASSETS
Investment in Acerus	1,041,000		0
LIABILITIES
Warrant derivative liability	0		0
Contingent consideration	0		0
Fair Value, Inputs, Level 2 [Member]
ASSETS
Investment in Acerus	0		0
LIABILITIES
Warrant derivative liability	0		0
Contingent consideration	0		0
Fair Value, Inputs, Level 3 [Member]
ASSETS
Investment in Acerus	0		0
LIABILITIES
Warrant derivative liability	276,000		0
Contingent consideration	$ 3,869,000		$ 664,000

Fair Value Considerations (De41

Fair Value Considerations (Details 1) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Initial Cost	$ 2,013,000
Unrealized Gains	0
Unrealized Losses	(972,000)
Fair Value	$ 1,041,000	$ 0

Fair Value Considerations (De42

Fair Value Considerations (Details 2) - Fair Value, Inputs, Level 3 [Member]	12 Months Ended
	Jun. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of June 30, 2015	$ 0
Warrant issuances	400,000
Reclassification of warrant liability to equity upon note conversion	(137,000)
Change in fair value included in earnings	13,000
Balance as of March 31, 2016	$ 276,000

Fair Value Considerations (De43

Fair Value Considerations (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	$ 1,041,000	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 6
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	75.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.32%
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years 10 months 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	75.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.986%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Benefit at statutory rate,Percentage	(34.00%)	(34.00%)
State income taxes, net of federal benefit, Percentage	(3.03%)	(2.79%)
Stock based compensation, Percentage	0.03%	5.51%
Interest on convertible debt, Percentage	0.27%	0.00%
Change in valuation allowance, Percentage	30.77%	30.95%
Reduction of net operating losses upon deconsolidation, Percentage	5.94%	0.00%
Other, Percentage	0.02%	0.03%
Net income tax provision (benefit, Percentage)	0.00%	(0.30%)
Benefit at statutory rate, Amount	$ (9,581,229)	$ (2,634,087)
State income taxes, net of federal benefit, Amount	(853,203)	(216,183)
Stock based compensation, Amount	7,156	426,725
Interest on convertible debt, Amount	75,148	0
Change in valuation allowance, Amount	8,672,155	2,397,527
Reduction of net operating losses upon deconsolidation, Amount	1,674,110	0
Other, Amount	5,863	2,108
Net income tax provision (benefit, Amount)	$ 0	$ (23,910)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Deferred tax assets (liabilities):
Deferred revenue	$ 0	$ 190,000
Deferred rent	5,000	0
Accrued expenses	445,000	73,000
Net operating loss carry forward	9,202,000	6,337,000
Intangibles	606,000	453,000
Share-based coompensation	327,000	0
Acquired in-process research and development	0	(2,779,000)
Unrealized loss on investment	360,000	0
Warrant liability	153,000	0
Inventory	192,000	0
Allowance for doubtful accounts	15,000	0
Total deferred income tax assets (liabilities)	11,305,000	4,274,000
Less: Valuation allowance	(11,305,000)	(4,274,000)
Total deferred income tax assets (liabilities)	$ 0	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Deferred Tax Assets, Operating Loss Carryforwards	$ 9,202,000	$ 6,337,000
Operating Loss Carryforwards	24,800,000	$ 17,100,000
Ampio Pharmaceuticals [Member]
Deferred Tax Assets, Operating Loss Carryforwards	$ 4,500,000

Commitments and Contingencies47

Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2016	May 31, 2016	Oct. 08, 2015	Apr. 16, 2015
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	$ 14,743,000
2,017	9,897,000
2,018	1,243,000
2,019	1,103,000
2,020	2,500,000
2,021	0
Thereafter	0
Primsol Business [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	750,000
2,017	750,000
2,018	0
2,019	0
2,020	0
2,021	0
Thereafter	0
Manufacturing Agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	3,000,000		$ 5,000,000
2,017	2,000,000
2,018	500,000
2,019	500,000
2,020	0
2,021	0
Thereafter	0
Service agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	204,000
2,017	204,000
2,018	0
2,019	0
2,020	0
2,021	0
Thereafter	0
Office Lease [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	317,000
2,017	142,000
2,018	145,000
2,019	30,000
2,020	0
2,021	0
Thereafter	0
Sponsored research agreement with related party [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	70,000
2,017	70,000
2,018	0
2,019	0
2,020	0
2,021	0
Thereafter	0
Prescription Database [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	1,902,000	$ 1,902,000
2,017	731,000
2,018	598,000
2,019	573,000
2,020	0
2,021	0
Thereafter	0
Natesto [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	8,500,000			$ 8,000,000
2,017	6,000,000			$ 6,000,000
2,018	0
2,019	0
2,020	2,500,000
2,021	0
Thereafter	$ 0

Commitments and Contingencies48

Commitments and Contingencies (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Commitments And Contingencies Rent Expense [Line Items]
Rent expense	$ 120,000	$ 51,000

Commitments and Contingencies49

Commitments and Contingencies (Details Textual) - USD ($)	Oct. 08, 2015	Jul. 31, 2016	Apr. 30, 2016	Oct. 31, 2015	Aug. 31, 2015	Jul. 31, 2015	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	May 31, 2016	Apr. 16, 2015
Unrecorded Unconditional Purchase Obligation [Line Items]
Contractual Obligation, Total								$ 14,743,000
Contractual Obligation, Due in Next Fiscal Year								9,897,000
Contractual Obligation, Due in Second Year								1,243,000
Payments For Service Agreement Contractual Obligations								310,000	$ 310,000
Primsol Business [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred				$ 142,000				1,892,000
Business Combination Consideration Transferred Inventory				102,000				102,000
Business Combination Consideration Transferred Product Inventory				40,000
Sponsored research agreement with related party [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Contractual Obligation, Total								$ 70,000
Agreement Termination Notice Period								30 days
Contractual Obligation, Due in Next Fiscal Year								$ 70,000
Contractual Obligation, Due in Second Year								0
Manufacturing Agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Contractual Obligation, Total	$ 5,000,000							3,000,000
Payment Of Contractual Obligations	$ 1,000,000		$ 500,000
Contractual Obligation, Due in Next Fiscal Year								2,000,000
Contractual Obligation, Due in Second Year								500,000
Natesto [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Contractual Obligation, Total								8,500,000			$ 8,000,000
Contractual Obligation, Due in Next Fiscal Year								6,000,000			$ 6,000,000
Contractual Obligation, Due in Second Year								0
Management Fee [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Management Fee Payable Per Month		$ 17,000				$ 30,000
Payment Of Contractual Obligations			500,000
Monthly Reduction In Contractual Obligation			$ 18,000
Paid on April 1, 2016 [Member] | Primsol Business [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred				500,000
Paid On July 1, 2016 [Member] | Primsol Business [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred				500,000
No Later Than September 30, 2016 [Member] | Primsol Business [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred				$ 250,000
Prescription Database [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Contractual Obligation, Total								1,902,000		$ 1,902,000
Contractual Obligation, Due in Next Fiscal Year								731,000
Contractual Obligation, Due in Second Year								598,000
Office Lease [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Operating Leases Monthly Base Rent Initial Year					$ 9,000		$ 3,000		$ 3,000
Lessee Leasing Arrangements, Operating Leases, Term of Contract					37 months		37 months
Operating Leases, Rent Expense					$ 318,000		$ 112,000
Contractual Obligation, Total								317,000
Contractual Obligation, Due in Next Fiscal Year								142,000
Contractual Obligation, Due in Second Year								$ 145,000

Convertible Promissory Notes (D

Convertible Promissory Notes (Details Textual) - USD ($)	May 06, 2016	Feb. 10, 2016	Feb. 10, 2015	Aug. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	May 31, 2016	Jan. 20, 2016
Debt Conversion [Line Items]
Debt Instrument, Face Amount				$ 5,200,000
Unamortized Debt Issuance Expense				401,000
Derivative Liability, Noncurrent				$ 103,000	$ 275,992	$ 0
Proceeds from Convertible Debt					$ 5,175,000	0
Debt Instrument, Convertible, Terms of Conversion Feature					At the insistence of the underwriters of the offering, all outstanding noteholders had signed lockup agreements which granted them an extra 10% on the conversion increasing it to 130% of shares calculated by dividing such note balance by $4.80,
Debt Related Commitment Fees and Debt Issuance Costs					$ 20,000
Placement Agents Cash Fee Percentage				8.00%	8.00%
Debt Instrument, Convertible, Beneficial Conversion Feature					$ 620,325	$ 620,325
Warrants Issued to Purchase of common stock	22,564	22,254
Warrants Exercise Price Per share	$ 4.80	$ 7.80
Warrants Exercisable Term	5 years
Convertible Promissory Notes [Member]
Debt Conversion [Line Items]
Proceeds from Convertible Debt					5,000,000
Debt Conversion, Original Debt, Amount	$ 1,050,000		$ 4,125,000
Debt Conversion Accrued Interest Amount	$ 78,000		$ 143,000
Debt Conversion, Converted Instrument, Shares Issued	305,559		656,591
Debt Instrument, Convertible, Beneficial Conversion Feature					$ 4,900,000
Debt Instrument, Convertible, Conversion Price							$ 4.80	$ 7.80
Debt Conversion, Converted Instrument, Warrants or Options Issued	305,559
Convertible Promissory Notes [Member] | Minimum [Member]
Debt Conversion [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Convertible Promissory Notes [Member] | Maximum [Member]
Debt Conversion [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					12.00%

Common Stock (Details Textual)

Common Stock (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Common Stock [Line Items]
Common Stock, Shares Authorized		100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized		50,000,000	50,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Common Stock, Shares, Outstanding		3,741,944	1,188,307
Stockholders' Equity, Reverse Stock Split		On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding (herein referred to collectively as the “Reverse Stock Splits”).
Warrants and Rights Outstanding	$ 20,000
Stock Issued During Period, Value, New Issues		$ 200,000
Payments of Stock Issuance Costs		$ 904,914	$ 0
Common Stock [Member]
Common Stock [Line Items]
Stockholders' Equity, Reverse Stock Split		one share of common stock for each 12 shares
Equity, Fair Value Disclosure	4,200,000
Stock Issued During Period, Value, New Issues		$ 3
Stock Issued During Period, Shares, New Issues		25,641
Warrant [Member]
Common Stock [Line Items]
Equity, Fair Value Disclosure	2,100,000
IPO [Member]
Common Stock [Line Items]
Proceeds from Issuance Initial Public Offering	$ 6,300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6
Warrants Expiration Term	5 years
Stock Issued During Period, Value, New Issues	$ 7,500,000
Stock Issued During Period, Shares, New Issues	1,562,500
Payments of Stock Issuance Costs	$ 1,200,000
Over-Allotment Option [Member]
Common Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.12
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	234,375
Underwriters Exercised of Over-Allotment Option	170,822

Equity Instruments (Details)

Equity Instruments (Details)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Assumptions Used To Determine Fair Value Options [Line Items]
Expected volatility	75.00%
Risk free interest rate	1.32%
Expected term (years)	5 years
Luoxis Diagnostics [Member]
Assumptions Used To Determine Fair Value Options [Line Items]
Expected volatility	75.00%	0.00%
Risk free interest rate, Minimum	1.16%
Risk free interest rate, Maximum	1.90%
Risk free interest rate		0.00%
Expected term (years)		0 years
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Minimum [Member] | Luoxis Diagnostics [Member]
Assumptions Used To Determine Fair Value Options [Line Items]
Expected term (years)	3 years 9 months
Maximum [Member] | Luoxis Diagnostics [Member]
Assumptions Used To Determine Fair Value Options [Line Items]
Expected term (years)	6 years 3 months

Equity Instruments (Details 1)

Equity Instruments (Details 1) - Luoxis Diagnostics [Member]	12 Months Ended
	Jun. 30, 2016$ / sharesshares
Number of Options
Number of Options, Beginning Balance	0
Number of Options, Granted	326,469
Number of Options, Exercised	0
Number of Options, Forfeited/Cancelled	(4,167)
Number of Options, Ending Balance	322,302
Number of Options Exercisable	139,798
Available for grant at June 30, 2016	511,032
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0
Weighted Average Exercise Price, Granted | $ / shares	18.01
Weighted Average Exercise Price, Exercised | $ / shares	0
Weighted Average Exercise Price, Forfeited/Cancelled | $ / shares	18.12
Weighted Average Exercise Price, Ending Balance | $ / shares	18.01
Weighted Average Exercise Price | $ / shares	$ 16.76
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Outstanding (in years)	9 years 3 months 29 days
Weighted Average Remaining Contractual Life, Excercisable (in years)	9 years 5 months 1 day

Equity Instruments (Details 2)

Equity Instruments (Details 2)	12 Months Ended
	Jun. 30, 2016$ / sharesshares
Number of Options Outstanding | shares	322,302
Weighted Average Exercise Price	$ 18.01
Number of Options Exercisable | shares	139,798
Weighted Average Remaining Contractual Life, Outstanding (in years)	9 years 3 months 29 days
Weighted Average Exercise Price	$ 16.76
Exercise Price Range One [Member]
Range of Exercise Prices	$ 6.72
Number of Options Outstanding | shares	16,668
Weighted Average Exercise Price	$ 6.72
Number of Options Exercisable | shares	16,668
Weighted Average Remaining Contractual Life, Outstanding (in years)	9 years 9 months 14 days
Weighted Average Exercise Price	$ 6.72
Exercise Price Range Two [Member]
Range of Exercise Prices	$ 18.12
Number of Options Outstanding | shares	301,467
Weighted Average Exercise Price	$ 18.12
Number of Options Exercisable | shares	123,130
Weighted Average Remaining Contractual Life, Outstanding (in years)	9 years 4 months 13 days
Weighted Average Exercise Price	$ 18.12
Exercise Price Range Three [Member]
Range of Exercise Prices	$ 55.56
Number of Options Outstanding | shares	4,167
Weighted Average Exercise Price	$ 55.56
Number of Options Exercisable | shares	0
Weighted Average Remaining Contractual Life, Outstanding (in years)	4 years 1 month 10 days
Weighted Average Exercise Price	$ 0

Equity Instruments (Details 3)

Equity Instruments (Details 3) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at June 30, 2016	$ 1,267,000
Weighted average remaining years to vest (in years)	2 years 7 months 28 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 903,000	$ 1,018,000
Research and Development Expense [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	89,000	519,000
Selling, General and Administrative Expenses [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 814,000	$ 499,000

Equity Instruments (Details 4)

Equity Instruments (Details 4) - $ / shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance	8,553	8,553
Granted in fiscal 2015		0
Share Based Compensation Share Warrants Expired		0
Warrants issued to placement agents for convertible promissory notes	22,254
Number of Warrants Outstanding, Ending Balance	2,201,627	8,553	8,553
Warrants issued to investors in connection with the registered offering	1,733,322
Warrants issued to placement agents for convertible promissory notes	22,564
Warrants issued to placement agents for the registered offering	109,375
aWarrants issued to convertible note holders who converted May 5, 2016	305,559
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 54.36	$ 54.36
Granted in fiscal 2015		0
Expired in fiscal 2015		0
Warrants issued to placement agents for convertible promissory notes	7.8
Weighted Average Exercise Price, Outstanding Ending Balance	6.19	$ 54.36	$ 54.36
Warrants issued to investors in connection with the registered offering	6
Warrants issued to placement agents for convertible promissory notes	4.80
Warrants issued to placement agents for the registered offering	6
Warrants issued to convertible note holders who converted May 5, 2016	$ 6
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding (in years)	4 years 8 months 16 days	2 years 11 months 1 day	3 years 11 months 1 day

Equity Instruments (Details 5)

Equity Instruments (Details 5)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	75.00%
Risk free interest rate	1.32%
Expected term (years)	5 years
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	75.00%	0.00%
Risk free interest rate, Minimum	1.07%
Risk free interest rate		0.00%
Risk free interest rate, Maximum	1.76%
Expected term (years)		0 years
Dividend yield	0.00%	0.00%
Maximum [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years
Minimum [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	4 years 2 months 12 days

Equity Instruments (Details Tex

Equity Instruments (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	May 31, 2016	Feb. 29, 2016	Aug. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 02, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance				143,236
Share Based Compensation Share Warrants Issued on Convertible Promisory Notes				22,254
Share Based Compensation Share Warrants Issued on Convertible Promisory Notes, Weighted Average Exercise Price				$ 7.8
Debt Instrument, Face Amount			$ 5,200,000
Placement Agents Cash Fee Percentage			8.00%	8.00%
Share Based Compensation Share Warrants Issued On Convertible Promisory Notes,Two				22,564
Share Based Compensation Share Warrants Issued On Convirtible Note Holders				305,559
Share Based Compensation Share Warrants Issued On Convertible Note Holders,Weighted Average Exercise Price				$ 6
Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering				109,375
Share Based Compensation Share Warrants Issued On Convertible Promisory Two Notes,Weighted Average Exercise Price				$ 4.80
Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering,Weighted Average Exercise Price				$ 6
Share Based Compensation Share Warrants Issued On Registered Offering				1,733,322
Share Based Compensation Share Warrants Issued On Registered Offering,Weighted Average Exercise Price				$ 6
Convertible Promissory Notes May 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 480,000
Share Based Compensation Share Warrants Issued On Convirtible Note Holders	305,559
Share Based Compensation Share Warrants Issued On Convertible Note Holders,Weighted Average Exercise Price	$ 6
Placement Agent warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Share Warrants Issued on Convertible Promisory Notes			22,254
Share Based Compensation Share Warrants Issued on Convertible Promisory Notes, Weighted Average Exercise Price		$ 7.80
Share Based Compensation Share Warrants Issued On Convertible Promisory Notes,Two		22,564
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 50,000	$ 87,000		$ 276,000
Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering	109,375
Share Based Compensation Share Warrants Issued On Convertible Promisory Two Notes,Weighted Average Exercise Price	$ 4.80
Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering,Weighted Average Exercise Price	$ 6
Investors Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Share Warrants Issued On Registered Offering	1,733,322
Share Based Compensation Share Warrants Issued On Registered Offering,Weighted Average Exercise Price	$ 6
2013 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense					$ 27,000
Luoxis 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total					$ 422,000
Reversal Of Allocated Share Based Compensation Expense				$ 433,000
2015 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance						833,334
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					833,334
Vyrix 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total					$ 189,000

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended				12 Months Ended
	Apr. 16, 2015	Mar. 31, 2014	Nov. 30, 2013	Jun. 30, 2013	Jun. 30, 2016	Aug. 31, 2015	Jun. 30, 2015	Jun. 30, 2014
Related Party Transaction [Line Items]
Common Stock, Shares, Issued					3,741,944		1,188,307
Debt Instrument, Face Amount						$ 5,200,000
Ampio [Member]
Related Party Transaction [Line Items]
Common Stock, Shares, Issued	396,816
Ampio [Member] | Second Installment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Property Subject to or Available for Operating Lease, Net, Total		$ 615,000
Ampio [Member] | Second Installment [Member] | After Amendment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Operating Lease Monthly Rental Payment				$ 6,000
Ampio [Member] | First Installment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Prepaid Expenses Amortization Period		60 months 15 days
Lease Agreements Maturity Period					March 2,019
Ampio [Member] | Ampio Loan Agreement [Member]
Related Party Transaction [Line Items]
Cash Advances For Short Term Loans			$ 500,000
Long-term Line of Credit		$ 3,000,000	$ 3,000,000
Debt Instrument, Term		1 year	1 year
Ampio [Member] | Ampio Loan Agreement [Member] | Vyrix Pharmaceuticals Inc [Member]
Related Party Transaction [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$ 4,000,000							$ 1,600,000
Ampio [Member] | Ampio Loan Agreement [Member] | Vyrix Pharmaceuticals Inc [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								3.11%
Ampio [Member] | Ampio Loan Agreement [Member] | Vyrix Pharmaceuticals Inc [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								3.32%
Ampio [Member] | Ampio Loan Agreement [Member] | Luoxis Diagnostics [Member]
Related Party Transaction [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	8,000,000							$ 3,000,000
Ampio [Member] | Ampio Loan Agreement [Member] | Luoxis Diagnostics [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								3.11%
Ampio [Member] | Ampio Loan Agreement [Member] | Luoxis Diagnostics [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								3.32%
Ampio [Member] | Promissory Note [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	10,000,000
Ampio [Member] | Promissory Note [Member] | Vyrix Pharmaceuticals Inc [Member]
Related Party Transaction [Line Items]
Debt Instrument, Decrease, Forgiveness	4,000,000
Ampio [Member] | Promissory Note [Member] | Luoxis Diagnostics [Member]
Related Party Transaction [Line Items]
Debt Instrument, Decrease, Forgiveness	$ 8,000,000

Employee Benefit Plan (Details

Employee Benefit Plan (Details textual)	12 Months Ended
	Jun. 30, 2016
Description of Defined Contribution Pension and Other Postretirement Plans	As of June 30, 2016, Aytu does not match employee contributions. Starting in fiscal 2017, the Company will match 50% of the first 6% contributed to the plan by employees.

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2016	Jun. 30, 2016	Jul. 27, 2016
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues		$ 200,000
Subsequent Event [Member] | Lincoln Park Capital Fund, LLC [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	133,690
Share Purchase Agreement, Maximum Amount Of Shares To Be Purchased			$ 10,000,000
Stock Issued During Period, Value, New Issues	$ 500,000
Stock Issued During Period, Shares, Issued for Services	52,500
Subsequent Event [Member] | Joseph Gunnar Co., LLC [Member]
Subsequent Event [Line Items]
Payments for Fees	$ 50,000
Additional Payments For Advisory Services	50,000
Subsequent Event [Member] | Fordham Financial Management, Inc. [Member]
Subsequent Event [Line Items]
Payments for Fees	50,000
Additional Payments For Advisory Services	$ 50,000
Subsequent Event [Member] | Executives, Employees, Directors and Consultants [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	441,999
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,000,000